Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

September 9, 2013
Cellceutix Acquires PolyMedix Assets from Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
Brilacidin

Beverly, MA — 09/09/13 — Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to announce that it has acquired substantially all of the assets of the company formerly known as PolyMedix, Inc., and previously traded as PYMX, a clinical stage biotechnology company which developed small-molecule drugs for the treatment of infectious diseases and innate immunity disorders. The acquisition includes the PolyMedix pipeline of nine compounds as well as the substantial equipment assets at PolyMedix’s 25,000-square-foot headquarters and laboratory.

IPIX acquired nine compounds.

http://www.ipharminc.com/press-release/2016/11/16/cellceutix-acquires-polymedix-assets-from-bankruptcy-court-gains-ownership-of-two-clinical-stage-drugs-multiple-compounds-and-equipment-assets